2016 Archived Content
AGENDA | ABOUT

Agenda

Now in its 11th year, the Neurotech Investing and Partnering Conference is the premier partnering and investing conference for the neurotechnology industry including pharmaceuticals, medical devices, software and diagnostics for the brain and nervous system.  Join these CEO, executives and investors at his important event.

7:30 - Breakfast and Registration

8:30 - Welcome Keynote and State of Neurotech Industry 2016


9:00 - Investing in Neurotech Panel

A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?


10:00 - Networking and Refreshment Break

10:30 - Treatments for Alzheimer's and Cognitive Disorders

As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies? Can earlier or more accurate diagnosis improve outcomes?


11:30 - Developments on the Horizon for Pain and Epilepsy

Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatment resistant populations for epilepsy and neuropathic pain.  Hear from leading companies on their approaches.


12:30 - Lunch

2:00 - Internal and External Research & Development

What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations with academic groups, research institutes, and platform companies?

  • Moderator: John Reppas, Director Public Policy, Neurotechnology Industry Organization  
  • Ajay Verma, VP Experimental Medicine, Biogen  
  • Jeff Erb, Sr. Director Business Development, Alliances and IP Portfolio Management, Medtronic  
  • Jeffrey Nye, Vice President Neuroscience Innovation and Scientific Partnership Strategy, J&J Innovation  

3:00 - Networking and Refreshment Break

3:30 - Strategies in CNS Drug and Device Development

Intelligent trial design, fundraising, and business development strategy is critical to the success of any neurotech venture. An insider panel will discuss specific tactics for improving drug and device development to navigate a path to approval and reimbursement. Case studies will demonstrate lessons learned in Alzheimer's, Parkinson's, depression, pain and more.


4:30 - Emerging Company Showcase

  • Scott Shandler, CEO, Longevity Biotech
  • Richard diMonda, COO, Sensory Innovations
  • Hagit Alon, Chief Scientific Officer, ALS Analyzer
  • Stacy Chambliss, Chief of Administration, Valencia Technologies
  • Mehran Talebinejad, CEO and Founder, NeuroQore
  • Travis Stiles, CEO and President, Novoron Bioscience
  • Val Goodfellow, CEO, Califia Bio
  • Henrik Kjeldsen, CEO, TRUUST Neuroimaging
  • Kenneth Rice, President and COO, LikeMinds

5:30 - Networking Reception
   

7:30 - Continental Breakfast & Registration

8:30 - Keynote

  • Polina Anikeeva, Assistant Professor, Massachusetts Institute of Technology

Rethinking the Brain Machine Interface

9:00 - Partnering and Licensing in Neurotech Panel

Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? With cutbacks in internal neuropharma R&D can we expect more partnering deals? Which companies are active in outlicensing deprioritized programs? What are priority indications and requirements for licensing deals? Where are the opportunities for neurodevice partnerships and where are the major players focusing their attentions?


10:00 - Networking and Refreshment Break

10:30 - Frontiers in Neurotechnology

In this session we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets including asthma, migraine, psychiatry, and epilepsy. Closed loop systems create the promise of reduced side effects and more targeted treatment.  New technology is yielding benefits in neurodiagnostics. Software solutions are tackling neuropsychiatric markets. Don't miss this preview of next generation products and companies.


11:30 - Next Generation Psychiatry

Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric illnesses represent a large portion of the neurotech market.  What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?


12:30 - Lunch

1:45 - Updates from NINDS

Stephanie Fertig, Director, Small Business Programs, NINDS

2:00 - Therapeutic and Gene Delivery in Neuroscience

Next generation strategies for crossing the blood brain barrier including devices, carrier technology and nanovesicle technology will be featured and discussed. Case studies in glioblastoma, Alzheimer's, Parkinson's and other areas will highlight the potential for new classes of treatments to be developed.


3:00 - Parkinson's and other Movement Disorders

Current treatments for movement disorders can improve functioning but suffer from side effects and “off” period especially as the disease progresses.  What is in the pipeline to address these issues?  Can disease modifying treatments alter the course of disease?  Can diagnostics improve treatment?


4:00 - Targeting Orphan Diseases

Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing.  Hear from companies developing treatments for ALS, lysosomal storage disorders, huntington's, and more. 


5:00 - Conference Concludes

#neurotech21
Submit a Speaker Proposal
Register
Spotlight Series
Video Highlights
Photo Gallery
View Sponsors
View Media Partners